IBIO(IBIO)
IBIO
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|
| Revenue Avg | $85,714 | $125,000 | $250,000 | $500,000 |
| Low | $85,714 | $125,000 | $250,000 | $500,000 |
| High | $85,714 | $125,000 | $250,000 | $500,000 |
| EBITDA Avg | $-51,428 | $-75,000 | $-150,000 | $-300,000 |
| Low | $-51,428 | $-75,000 | $-150,000 | $-300,000 |
| High | $-51,428 | $-75,000 | $-150,000 | $-300,000 |
| EBIT Avg | $-51,428 | $-75,000 | $-150,000 | $-300,000 |
| Low | $-51,428 | $-75,000 | $-150,000 | $-300,000 |
| High | $-51,428 | $-75,000 | $-150,000 | $-300,000 |
| Net Income Avg | $-3M | $-4M | $-7M | $-10M |
| Low | $-4M | $-5M | $-7M | $-10M |
| High | $-3M | $-4M | $-7M | $-10M |
| EPS Avg | $-0.31 | $-0.40 | $-0.68 | $-0.95 |
| Low | $-0.35 | $-0.43 | $-0.68 | $-0.95 |
| High | $-0.26 | $-0.37 | $-0.68 | $-0.95 |
| Analysts (Rev / EPS) | 5 / 5 | 4 / 2 | 2 / 1 | 2 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 |
|---|---|---|---|---|
| Revenue Avg | $33,333 | — | — | — |
| Low | $33,333 | — | — | — |
| High | $33,333 | — | — | — |
| EBITDA Avg | $-19,999 | — | — | — |
| Low | $-19,999 | — | — | — |
| High | $-19,999 | — | — | — |
| EBIT Avg | $-19,999 | — | — | — |
| Low | $-19,999 | — | — | — |
| High | $-19,999 | — | — | — |
| Net Income Avg | $-9M | $-9M | $-9M | $-10M |
| Low | $-10M | $-9M | $-9M | $-10M |
| High | $-8M | $-9M | $-9M | $-10M |
| EPS Avg | $-0.07 | $-0.07 | $-0.08 | $-0.08 |
| Low | $-0.09 | $-0.07 | $-0.08 | $-0.08 |
| High | $-0.06 | $-0.07 | $-0.08 | $-0.08 |
| Analysts (Rev / EPS) | 2 / 3 | — / 1 | — / 1 | — / 1 |